Sage Journals: Discover world-class research

Abstract

Introduction:

Brodalumab is an interleukin-17 receptor blocker that is effective for the treatment of psoriasis. However, due to a Food and Drug Administration black box warning on depression and suicide, many providers are hesitant to use this agent despite its efficacy.

Methods:

We present the cases of 2 brothers seen at our clinic with treatment-resistant psoriasis who were both successfully treated with brodalumab, despite failing 6 other biologics. We also review the safety profile of brodalumab regarding the currently available evidence on the increased risk of suicidality or depression in patients treated with brodalumab.

Results:

Both patients achieved completely clear skin and maintained clearance on brodalumab.

Discussion:

Brodalumab appears to be an effective agent in severe treatment-resistant cases of psoriasis. In addition, a causal relationship between increased risk of suicidality or depression and brodalumab use has not been established.

Keywords

interleukin 17 inhibitor biologic treatment psoriasis case report brodalumab treatment outcomes

Get full access to this article

View all access options for this article.

References

Lebwohl

Strober

Menter

, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318–1328.

Griffiths

Reich

Lebwohl

, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–551.

Langley

Elewski

Lebwohl

, et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338.

Reich

Armstrong

Langley

, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831–839.

Blauvelt

Papp

Gottlieb

, et al. A head-to-head comparison of ixekizumab versus guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety, and speed of response from a randomized, double-blinded trial. Br J Dermatol. 2019.

Ortho dermatologics. Siliq [package insert]. U.S. Food and Drug Administration Website. Updated February, 2017. Accessed August 11, 2019. Fda.Gov Published 2017.

Lebwohl

Papp

Marangell

, et al. Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials. J Am Acad Dermatol. 2018;78(1):81–89.e85.

Papp

Reich

Paul

, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175(2):273–286.

Pardridge

. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005;2(1):3–14.

10.

Gananca

Oquendo

Tyrka

Cisneros-Trujillo

Mann

Sublette

. The role of cytokines in the pathophysiology of suicidal behavior. Psychoneuroendocrinology. 2016;63:296–310.

11.

Gooderham

Gavino-Velasco

Clifford

MacPherson

Krasnoshtein

Papp

A review of psoriasis, therapies, and suicide. J Cutan Med Surg. 2016;20(4):293–303.

12.

Pavelka

Chon

Newmark

Lin

Baumgartner

Erondu

. A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate. J Rheumatol. 2015;42(6):912–919.

13.

Targan

Feagan

Vermeire

, et al. A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn’s disease. Am J Gastroenterol. 2016;111(11):1599–1607.

Brodalumab for Treatment-Resistant Psoriasis: Case Reports and Safety Update

Abstract

Introduction:

Methods:

Results:

Discussion:

Keywords

Get full access to this article

References